The latest report from EP Vantage reviews the performance of the pharma & biotech industry in the first half of 2014 and reveals that while an M&A frenzy accounting for nearly $90 billion of equity set the pace for the first half of 2014, a slowdown in IPOs and six months of volatile market activity could tarnish the year’s shimmering start.
Key findings include:
IPOs peaked in the first quarter at $2.1 billion, but fell back to $913 million to end the first half of the year
Companies raised more than $3 billion in venture capital in the first six months, putting the sector on pace to exceed the $5.9 billion raised in 2007
The first seven months of 2014 saw the FDA approve 27 novel agents, which are forecast to generate $7 billion in US sales over the next five years
To download this report, please confirm your details on the form opposite.